Annual Financial Report

AI SummaryClose X

The Biotech Growth Trust PLC reported a strong financial year ended 31 March 2026, with net asset value per share increasing by 73.4% to 1,414.6p, significantly outperforming the benchmark NASDAQ Biotechnology Index which rose 35.0%. Shareholders' funds grew to £281.9 million from £221.2 million in the prior year, while the share price saw a total return of 67.1%. The company repurchased 7,183,277 shares for £69.5 million to manage its discount to net asset value, which widened to 10.9% by year-end. No dividend was recommended for the year, reflecting the low yield from the biotechnology sector. The company experienced a currency headwind due to sterling's strength against the US dollar.

Disclaimer*

UK 100

Latest directors dealings